2 doses. 1 month. Done.

 

Scary Mommy
[[link removed]]
[[link removed]]

Sep 08, 2022

 

[[link removed]]
[[link removed]] 
Presented by HEPLISAV-B
[[link removed]]
2 doses. 1 month. Done.
[[link removed]] 
Your children likely received their hepatitis B vaccine at birth, but if you
were born before 1991, you may be living unprotected. Now the CDC says it's time
for adults aged 19-59* to get caught up—parents, that means you!

Hepatitis B is an incurable liver infection caused by the hepatitis B virus.
Prevention with vaccination is essential for protection.

 

[[link removed]]
[[link removed]] 
Ask your pharmacist for HEPLISAV-B.
[[link removed]] 2
doses. 1 month. Done.

We know making time for your health can be a challenge with a busy schedule.
Other adult hepatitis B vaccines require at least 3 doses and take 6 months to
complete.

Vaccination with HEPLISAV-B is the fastest way to catch up—2 doses. 1 month.
Done.

See what to expect with HEPLISAV-B.

  Learn More
[[link removed]]
[[link removed]]

 

  *The CDC also recommends hepatitis B vaccination for adults aged ≥60 with risk
factors. Adults aged ≥60 without risk factors may receive hepatitis B
vaccination.

INDICATION

HEPLISAV-B is indicated for the prevention of infection caused by the hepatitis
B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

If you have a history of severe allergic reaction after a previous dose of any
hepatitis B vaccine, or to any ingredient of HEPLISAV-B, including yeast, do not
take HEPLISAV-B.

HEPLISAV-B must be given by a medical professional, who will monitor you
afterwards to check for allergic reaction.

If you are immunocompromised, or receiving immunosuppressant therapy, you may
have less of an immune response to HEPLISAV-B.

Some people have hepatitis B infection without being aware of it or showing any
symptoms. If you already have hepatitis B present in your body, HEPLISAV-B may
not prevent hepatitis B infection.

The most common side effects reported by patients within 7 days of vaccination
with HEPLISAV-B were pain at the site of injection (23%-39%), tiredness
(11%-17%), and headache (8%-17%).

Please see full Prescribing Information.
[[link removed]]

US-22-00-00333

 

You're receiving this email because you signed up to receive communications from
BDG Media. If you believe this has been sent to you in error, please safely
unsubscribe
[[link removed]].

315 Park Ave. South, New York, NY 10010

Copyright 2022 BDG Media, Inc. All rights reserved.

View in browser
[[link removed]]